Compare · MDT vs SMLR
MDT vs SMLR
Side-by-side comparison of Medtronic plc. (MDT) and Semler Scientific Inc. (SMLR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDT and SMLR operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- MDT is the larger of the two at $101.90B, about 216.5x SMLR ($470.7M).
- Over the past year, MDT is down 6.1% and SMLR is down 37.1% - MDT leads by 31.0 points.
- MDT has hit the wire 22 times in the past 4 weeks while SMLR has been quiet.
- MDT has more recent analyst coverage (25 ratings vs 6 for SMLR).
- Company
- Medtronic plc.
- Semler Scientific Inc.
- Price
- $79.42+0.08%
- $20.34-5.02%
- Market cap
- $101.90B
- $470.7M
- 1M return
- -8.22%
- +16.67%
- 1Y return
- -6.10%
- -37.13%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 22
- 0
- Recent ratings
- 25
- 6
Medtronic plc.
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Semler Scientific Inc.
Semler Scientific, Inc. develops, manufactures, and markets proprietary products that assist healthcare providers to evaluate and treat patients with chronic diseases in the United States. The company's products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition. Its products serve cardiologists, internists, nephrologists, endocrinologists, podiatrists, and family practitioners, as well as healthcare insurance plans, integrated delivery networks, independent physician groups, and companies contracting with the healthcare industry, such as risk assessment groups. The company offers its products through salespersons and distributors. Semler Scientific, Inc. was incorporated in 2007 and is headquartered in Santa Clara, California.
Latest MDT
- FDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM Therapy
- Chief Accounting Officer Blomquist Denise L. was granted 1,508 units of Ordinary Shares and covered exercise/tax liability with 318 units of Ordinary Shares, increasing direct ownership by 10% to 13,262 units (SEC Form 4)
- Director Nabel Elizabeth G was granted 2,111 units of Ordinary Shares and covered exercise/tax liability with 207 units of Ordinary Shares, increasing direct ownership by 11% to 19,584 units (SEC Form 4)
- Director Powell Kendall J was granted 2,111 units of Ordinary Shares and covered exercise/tax liability with 207 units of Ordinary Shares, increasing direct ownership by 4% to 51,380 units (SEC Form 4)
- Director Lofton Kevin E was granted 2,111 units of Ordinary Shares and covered exercise/tax liability with 207 units of Ordinary Shares, increasing direct ownership by 23% to 10,140 units (SEC Form 4)
- Director Jellison William R was granted 1,444 units of Ordinary Shares, increasing direct ownership by 29% to 6,444 units (SEC Form 4)
- Director Lee Joon Sup was granted 1,803 units of Ordinary Shares (SEC Form 4)
- Director Lewis Gregory P was granted 2,111 units of Ordinary Shares and covered exercise/tax liability with 207 units of Ordinary Shares, increasing direct ownership by 49% to 5,754 units (SEC Form 4)
- Director Hogan Randall J was granted 2,111 units of Ordinary Shares and covered exercise/tax liability with 207 units of Ordinary Shares, increasing direct ownership by 4% to 48,998 units (SEC Form 4)
- Director Groetelaars John P was granted 1,444 units of Ordinary Shares (SEC Form 4)
Latest SMLR
- SEC Form SCHEDULE 13G filed by Semler Scientific Inc.
- SEC Form 15-12G filed by Semler Scientific Inc.
- SEC Form EFFECT filed by Semler Scientific Inc.
- SEC Form EFFECT filed by Semler Scientific Inc.
- SEC Form S-8 POS filed by Semler Scientific Inc.
- SEC Form S-8 POS filed by Semler Scientific Inc.
- SEC Form S-8 POS filed by Semler Scientific Inc.
- SEC Form S-8 POS filed by Semler Scientific Inc.
- SEC Form S-8 POS filed by Semler Scientific Inc.
- SEC Form S-8 POS filed by Semler Scientific Inc.